Topics: Research and Development, FDA, Patents, Intellectual Property
From accessing medicines to intellectual property to drug safety, PhRMA is devoted to advancing public policies that support innovative medical research, improve treatments and yield real results.
On Monday, Senator Leahy highlighted President Obama's Chamber of Commerce remarks in which he called for a need to reform our patent system. We're quick to recognize that patents - along with other forms of intellectual property - are a crucial incentive to innovate; in other words, they facilitate the work required to turn an idea into a usable product.
Senator Leahy's statement also reminded us of something that we often take for granted, however: the importance of policies that spur new ideas. Innovation is cyclical. Biopharmaceutical research companies don't rest on their laurels when a new medicine gains FDA approval and reaches the market. They dig in their heels and get to work, whether it's developing a product no one has ever dreamt of before or turning an existing technology into something much better than previously thought.
Just as we celebrate today's medical breakthroughs, we need a reliable patent system that helps to stimulate tomorrow's big ideas.
Topics: Research and Development, FDA, Patents, Intellectual Property
Pharmaceutical Research and Manufacturers of America®
950 F Street, NW Suite 300, Washington, DC 20004
Please be advised that this page contains pixel tags. To learn more about what pixel tags are, why and how
we and third parties use pixel tags, and how that use affects you, visit our privacy policy and review
"1. Information Collection."